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Abstract
Background: Hepatitis C virus (HCV) circulates as quasispecies (QS), whose evolution is
associated with pathogenesis. Previous studies have suggested that the use of thermostable
polymerases without proofreading function may contribute to inaccurate assessment of HCV QS.
In this report, we compared non-proofreading (Taq) with proofreading (Advantage High Fidelity-
2; HF-2) polymerases in the sensitivity, robustness, and HCV QS diversity and complexity in the
second envelope glycoprotein gene hypervariable region 1 (E2-HVR1) on baseline specimens from
20 patients in the HALT-C trial and in a small cohort of 12 HCV/HIV co-infected patients. QS
diversity and complexity were quantified using heteroduplex mobility assays (HMA).
Results: The sensitivities of both enzymes were comparable at 50 IU/ml, although HF-2 was more
robust and slightly more sensitive than Taq. Both enzymes generated QS diversity and complexity
scores that were correlated (r = 0.68; p < 0.0001, and r = 0.47; p < 0.01; Spearman's rank
correlation). QS diversity was similar for both Taq and HF-2 enzymes, although there was a trend
for higher diversity in samples amplified by Taq (p = 0.126). Taq amplified samples yielded
complexity scores that were significantly higher than HF-2 samples (p = 0.033). HALT-C patients
who were HCV positive or negative following 20 weeks of pegylated IFN plus ribavirin therapy had
similar QS diversity scores for Taq and HF-2 samples, and there was a trend for higher complexity
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scores from Taq as compared with HF-2 samples. Among patients with HCV and HIV co-infection,
HAART increased HCV QS diversity and complexity as compared with patients not receiving
therapy, suggesting that immune reconstitution drives HCV QS evolution. However, diversity and
complexity scores were similar for both HF-2 and Taq amplified specimens.
Conclusion: The data suggest that while Taq may overestimate HCV QS complexity, its use does
not significantly affect results in cohort-based studies of HCV QS analyzed by HMA. However, the
use of proofreading enzymes such as HF-2 is recommended for more accurate characterization of
HCV QS in vivo.
Background
HCV exists as quasispecies (QS) in infected individuals,
consisting of a predominant viral variant and related, yet
genetically distinct minor variants [1]. The study of HCV
QS has historically focused on the hypervariable region 1
(HVR1) of the second envelope (E2) glycoprotein gene
[2,3], the most variable region of the HCV genome. Early
studies revealed that E2-HVR1 is a target of neutralizing
antibodies [4-10]. Immune pressure is thought to be
chiefly responsible for the fixation of the mutations in this
region of the E2 gene.
HCV QS have been analyzed in many different patient
cohorts. HVR1 QS evolution may reflect progression of
liver disease [11-15]. HCV QS also reflect the outcome of
acute HCV infection [16], and responses to antiviral ther-
apy [17]. More recent studies have investigated the effect
of HCV/HIV co-infection on HCV QS dynamics [18,19].
In the current study, we analyzed 20 baseline samples
from the HALT-C trial and 12 HCV-HIV co-infected
patient samples. The HALT-C study is a randomized
multi-center clinical trial to assess the effects of long-term
pegylated interferon-α (peg-IFN) therapy on the progres-
sion of liver fibrosis and development of decompensated
liver disease in hepatitis C patients who are non-respond-
ers to prior pegylated IFN plus ribavirin therapy [20,21].
Viral QS have been analyzed by many techniques. Clon-
ing and sequencing is the gold standard. Electrophoretic
mobility-based assays, including single strand conforma-
tion polymorphism analysis (SSCP) and heteroduplex
mobility analysis (HMA) allow determination of HCV QS
heterogeneity without the need for sequencing (reviewed
in [22]). HMA was originally described for analyzing the
sequence heterogeneity of the envelope gene of human
immunodeficiency virus (HIV) [23,24]. HMA involves
hybridization of a radioactive probe generated from a QS
variant to either heterogeneous PCR reaction products
derived by direct PCR amplification from clinical speci-
mens, or to homogeneous HVR1 sequences derived from
cloned QS variants (clonal frequency analysis, CFA; [25]).
Hybridizations between the probe and various target
sequences result in the formation of double stranded
DNA molecules (heteroduplexes) that produce shifts
when the hybrids are separated on non-denaturing poly-
acrylamide gels. The shifts are determined by comparison
to a homoduplex probe control (probe hybridized to
itself). The extent of the heteroduplex shift compared to
the homoduplex control is proportional to the degree of
sequence divergence between the two DNA molecules. We
have shown an excellent correlation between genetic
diversity and complexity (number of variants) of individ-
ual QS variants derived by HMA as compared with stand-
ard cloning and sequencing of the HVR1 [11-13,25,26].
Moreover, HMA can be applied to studies of HCV QS evo-
lution, in the context of therapy, transmission, and patho-
genesis [11,12,25-29].
Taq polymerase is the enzyme used in most studies of
HCV QS analysis. However, given that Taq lacks proof-
reading activity, mathematical debates have been raised to
suggest that QS evolution is overestimated by Taq induced
mutations [30]. Indeed, in one report, use of Taq
increased the proportion of minor QS variants [31], and
we have found that, in general, QS diversity is lower if
proof-reading enzymes are used instead of Taq [32]. But
the question arises as to whether Taq induced mutations
affect the outcomes/conclusions in cohort-based studies
on HCV QS. Thus, in the current study, we compared Taq
and HF-2 polymerases in terms of sensitivity and robust-
ness, and in terms of evaluating HCV QS diversity and
complexity as assessed by CFA of the E2-HVR1 on base-
line specimens from 20 patients in the HALT-C trial and
12 HCV-HIV co-infected patients receiving or not receiv-
ing HAART.
Results
Clinical characteristics of the HALT-C and HCV-HIV co-
infected patients are depicted in Tables 1 and 2. For HALT-
C patients, all patients were infected with HCV genotype
1, with 10/20 (50%) being genotype 1a, and 7/20 (35%)
being genotype 1b. Subtype designations were not
obtained for 2/20 (10%) genotype 1 patients, and 1
patient was designated as type 1a or 1b. 16/20 (80%)
patients were male. The average age of patients was 48.9
years, and average viral load was 106.56 IU/ml (3.6 × 106
IU/ml). For the HCV/HIV co-infected patients, all patients
were infected with HCV genotype 1, with 10/12 (83%)
Virology Journal 2005, 2:41 http://www.virologyj.com/content/2/1/41
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Table 1: Clinical and virological characteristics of the 20 HALT-C patients.
Patient Age Gender Genotype Serum HCV 
RNA at W00 
(log10)
Diversity Complexity
Taq HF-2 Taq HF-2
1 52 M 1a 6.55 0.9953 1.0000 7 1
2 54 F 1b 6.49 0.9905 1.0000 5 1
3 51 M 1a/b 6.99 0.9958 1.0000 5 1
4 42 M 1a 6.81 0.9877 0.9894 6 2
5 56 M 1a 7.13 0.9979 1.0000 4 1
6 42 M 1 6.55 0.9903 0.9912 8 6
7 73 M 1b 6.78 0.9892 0.9877 7 5
8 45 M 1 6.37 0.9193 0.9805 7 6
9 53 M 1a 7.06 0.9954 1.0000 2 1
10 47 M 1b 6.35 0.9845 0.9994 4 3
11 19 M 1b 5.72 0.9964 0.9994 2 2
12 49 M 1a 7.06 0.9979 0.9986 3 3
13 42 F 1b 6.26 0.9993 0.9781 2 2
14 42 M 1a 7.30 0.9810 0.9685 8 9
15 61 M 1b 5.85 0.9858 0.9624 4 5
16 54 M 1b 6.93 0.9047 0.9409 6 9
17 45 F 1a 6.72 0.9962 0.9917 2 5
18 47 F 1a 6.14 0.9966 0.9984 4 2
19 50 M 1a 6.37 0.9962 0.9968 4 3
20 53 M 1a 5.81 0.989 0.9943 6 5
AVG 48.85 6.56 0.9845 0.9889 4.8 3.6
HCV genotypes were determined by INNO-LiPA. HCV RNA was quantified with the Roche COBAS Monitor assay, and is expressed as log10 IU/
mL. QS heterogeneity was assessed using the clonal frequency analysis (CFA) technique. Diversity scores represent the average heteroduplex 
mobility ratios (HMR) for either Taq or HF-2 enzymes. Complexity scores represent the total number of distinct gel shift variants analyzed by CFA. 
W00 represents the week 0 or baseline sample. AVG represents average.
Table 2: Clinical and virological characteristics of the 12 HCV/HIV co-infected patients.
Patient Age Gender Genotype Serum HCV 
RNA (log10)
Diversity Complexity
Taq HF-2 Taq HF-2
1 49 F 1a 6.37 0.9856 0.9616 4 5
2 40 M 1a 5.96 0.9987 0.9978 2 2
3 36 F 1b 5.53 1.0000 1.0000 1 1
4 38 M 1a 6.75 0.9313 0.9715 8 11
5 42 M 1a 6.94 1.0000 1.0000 1 1
6 40 M 1b 5.55 0.9912 0.9997 5 2
7 41 M 1a 6.39 0.9909 1.0000 6 1
8 45 F 1a 6.25 0.9856 0.9468 4 7
9 47 M 1a 5.68 0.9945 0.9996 2 2
10 41 M 1a 5.92 0.9575 0.9430 10 10
11 61 F 1a 6.83 0.9389 0.9283 7 6
12 51 M 1a 6.99 0.9890 0.9638 2 7
AVG 44.2 6.53 0.9803 0.9760 4.33 5.0
HCV genotypes were determined by INNO-LiPA, while HCV RNA was quantified with the Roche COBAS Monitor assay, and is expressed a 
log10IU/mL. QS heterogeneity was assessed using the clonal frequency analysis (CFA) technique. Diversity scores represent the average 
heteroduplex mobility ratios (HMR) for either Taq or HF-2 enzymes. Complexity scores represent the total number of distinct gel shift variants 
analyzed by CFA. AVG represents average.
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being genotype 1a, and 2/12 (17%) being genotype 1b.
Eight of 12 patients (67%) were male. The average age of
the co-infected patients was 44 years, and average viral
load was 106.53 IU/ml (3.3 × 106 IU/ml).
Figure 1 presents the sensitivity of the E2-HVR1 PCR using
Taq versus HF-2 polymerases. Serial dilutions of the HCV
international standard were run through the assay, and
PCR products were visualized on agarose gels. As shown
in Fig. 1, Taq produced amplification products at all dilu-
tions, with 1 of 2 duplicate samples giving a signal at a
dilution of 50 IU/ml. However, the HF-2 enzyme pro-
duced more PCR product than Taq at all dilutions and
both replicates were positive at 50 IU/ml. Below each lane
is the result of Roche COBAS Amplicor qualitative RT-PCR
testing of the same serum specimens, which are scored as
positive (+) or negative (-). At 50 IU/ml the Amplicor test
was positive for 1 of the 2 duplicates. The data indicate
that the sensitivities of the Taq and HF-2 enzymes were
similar to the Amplicor assay, and the HF-2 enzyme was
slightly more robust and sensitive than Taq polymerase.
The 2 enzymes produced QS diversity and complexity
scores that were correlated (Linear regression analysis: R-
squared: 0.4113, p < 0.0001 for diversity, and R-squared:
0.311, p < 0.001 for complexity; Spearman's rank correla-
tion test: r= 0.68, p < 0.0001 for diversity, and r = 0.47, p
< 0.01 for complexity). Figure 2 depicts representative
clonal frequency analyses (CFA) of HALT-C baseline sam-
ples from patient 9 (figure 2A), patient 6 (figure 2B) and
patient 16 (figure 2C), amplified by both Taq and HF-2
enzymes. The first lane of each gel represents the
homoduplex probe control, obtained by hybridizing the
radiolabeled probe to its non-labeled self. The homodu-
plex (designated as "HD" in the figure) serves as the refer-
ence point for all comparisons of individual clonal gel
shift patterns. The second lane of each gel represents the
heterogenous (ie non-clonal) PCR product, which con-
tains all the QS variants amplified from the serum sample,
and is designated as "H" in the figure. For each CFA, a shift
control is also included, which involves the hybridization
of the probe hybridized to a different HVR1 PCR product.
In all cases, shift controls produced clearly identifiable
shifts, indicating the hybridization reaction and electro-
phoresis was successful (data not shown). An internal
control is also derived from a comparison of the heterog-
enous PCR product ("H") versus CFA gel shift patterns. If
the gel shift patterns of the individual clones are repre-
sentative of the heterogenous PCR product, the CFA was
successful [11,26,27].
As shown in Figure 2A, patient 9 had very few discernible
gel shifts, and the shifts themselves were not very distinct
from the homoduplex probe control. The same pattern
was observed when either Taq or HF-2 was used. Indeed,
HMR scores for Taq and HF-2 (0.9954 vs. 1.0000) were
Comparison of the sensitivity of the E2-HVR1 PCR using Taq and HF-2 enzymesFigure 1
Comparison of the sensitivity of the E2-HVR1 PCR using Taq and HF-2 enzymes. RNA was extracted from duplicate serial dilu-
tions of a WHO HCV standard and RT-PCR was performed with Taq and HF-2 enzymes. The dilutions corresponded to 
50,000 (5K), 1,000 (1K), 500, 100, and 50 IU/ml, and are indicated above each lane. The position of the 176 bp E2-HVR1 is indi-
cated with arrows. MW represents the 100 base pair DNA molecular weight marker. Below each lane is the result of testing of 
the same dilution of the standard with the Roche COBAS Amplicor assay. The result of this test gives a positive (+) or negative 
(-) result.
5K   1K 500  100    50  NEG
E2-HVR1
E2-HVR1
MW
Taq
HF-2
Amplicor:  +    +   +    +   +    +   +    +   +    -   -  -
HCV (IU/ml):
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similar, as were the complexity scores for samples
analyzed by Taq and HF-2 (2 vs.1 variants). The flat line
nature of the CFA pattern was not due to a failure of the
hybridization reaction, because the shift control (the
same probe hybridized to a different HVR1 PCR product)
produced a significant gel shift (data not shown). Moreo-
ver, the same pattern was observed when the heteroge-
nous PCR product (prior to cloning) was hybridized to
the probe (Figure 2A, lane 2). The results indicate that this
patient had minimal QS heterogeneity. In contrast,
patient 6 had clearly identifiable gel shifts when com-
pared to the probe (Figure 2B). The same pattern was
observed whether the reaction was performed with Taq or
HF-2 enzyme. Again, Taq and HF-2 scores were similar
both for HMR (0.9903 vs 0.9912 (Taq vs. HF-2)) and
complexity (8 vs. 6 variants (Taq vs. HF-2)). The gel shift
Representative autoradiograms of clonal frequency analyses of HALT-C patients with low (patient 9, panel A), intermediate (patient 6, panel B) an  hi h (patient 16, panel C) QS diver ity and complex tyFigure 2
Representative autoradiograms of clonal frequency analyses of HALT-C patients with low (patient 9, panel A), intermediate 
(patient 6, panel B) and high (patient 16, panel C) QS diversity and complexity. E2-HVR1 RT-PCRs were performed with Taq 
and HF-2 enzymes. PCR products were cloned as described in the Materials and Methods, and individual colonies were picked 
and re-amplified. Lane 1 represents the homoduplex (HD) control and represents the probe hybridized to itself. Lane 2 repre-
sents the heteroduplex profile of the heterogenous (ie not cloned) E2-HVR1 PCR product and is designated "H". Panels D and 
E are graphical summaries of HMR and Complexity in the 3 patients.
A.
Patient 9
HD
Patient 6
B.
Taq
HF-2
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HF-2
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pattern observed with CFA was similar to the pattern
observed when heterogenous PCR product from the same
time point was hybridized to the probe (Figure 2B, lane
2). Patient 16 displayed even more marked QS heteroge-
neity (Figure 2C). This was quantitated both in terms of
HMR (0.9047 vs. 0.9409 (Taq vs. HF-2)) and complexity
(6 vs. 9 variants, (Taq vs. HF-2)). The bar graphs in Figures
2D and 2E summarize the diversity (HMR) and complex-
ity data, and confirm the progressively increasing QS
diversity and complexity in patients 9, 6, and 16. Note
that increased QS diversity is reflected as a decrease in
HMR.
Furthermore, Taq gave lower HMRs indicative of higher
diversity in all 3 patients, and higher complexity scores in
2 of the 3 patients. The data suggest that Taq may overes-
timate HCV QS genetic diversity and complexity when
analyzed by HMA.
To further examine this issue, CFA was performed for 20
HALT-C baseline specimens, and QS diversity scores and
complexity scores were determined. These data are sum-
marized in Table 1 and depicted graphically in Figure 3.
Figure 3A depicts the HMR results, while Figure 3B depicts
the complexity scores for the 20 HALT-C patients ana-
lyzed by both enzymes. The average HMR for Taq
amplified samples was 0.9845 (range 0.9047–0.9993),
while the average HMR for the HF-2 enzyme was 0.9889
(range 0.9407–1.000). Taq samples appeared somewhat
more diverse than HF-2 samples. However, this trend did
not reach statistical significance (p = 0.126). Similarly, the
average complexity for Taq amplified samples was 4.8
(range 2–8), while the average complexity for the HF-2
enzyme was 3.6 (range 1–9). QS complexity scores were
higher in samples amplified by Taq as compared with
samples amplified by HF-2 (p = 0.033).
Cumulatively, the data indicate that Taq overestimates
HCV QS genetic diversity and complexity. However, what
is not clear is whether this tendency for overestimation by
Taq impacts QS scores in clinical studies.
To address this issue, we grouped the 20 HALT-C patients
according to whether they were serum positive or negative
for HCV RNA following 20 weeks of pegylated IFN plus
ribavirin therapy. By this criterion, 6 patients were HCV
RNA negative and 14 patients were HCV RNA positive at
week 20. Figure 4 presents the HMR and complexity
scores for the 2 groups of patients and demonstrates that
HMR and complexity scores were similar among patients
who were HCV RNA negative or positive following 20
weeks of peg-IFN plus ribavirin, regardless of the enzyme
used. There was a trend for HF-2 samples generating lower
complexity scores as compared to Taq samples, but the
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) values in samples processed with T q r HF-2 polym ras s in HALT-C baseline specimensFigure 3
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) values in samples processed 
with Taq or HF-2 polymerases in HALT-C baseline specimens. The box plots represent the means and ranges of the HMR and 
complexity scores for 400 HVR1 clones amplified by each polymerase, for a total of 800 clones (20 patients × 20 clones/patient 
× 2 enzymes). Error bars represent standard deviations. Significance values above each panel were derived from Wilcoxon 
Signed Ranks tests.
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difference was not significant. Note also that the lower
complexity scores from HF-2 as compared with Taq proc-
essed samples among week 20 responders and non-
responders mirrored the results when all patients were
considered together (Figure 3).
To further determine if the choice of amplification
enzyme affects results in patient cohort studies, we com-
pared QS diversity and complexity on samples from 12
HCV/HIV co-infected patients treated or not treated with
highly active anti-retroviral therapy (HAART). As shown
in Figure 5, patients receiving HAART had increased QS
diversity (shown as a decrease in HMR in panel A) and
complexity (panel B) as compared to patients who did not
receive HAART. This trend was apparent regardless of
whether Taq and HF-2 were used. The increase in diversity
and complexity scores upon HAART did not reach statisti-
cal significance. Moreover, HMR and complexity scores
were not significantly different between Taq and HF-2
samples. In fact, HAART-samples amplified by HF-2
showed a trend for higher complexity scores (complexity
= 4) as compared with Taq samples (complexity = 3.2).
These data suggest that although Taq may overestimate
QS complexity, it likely does not mask potentially impor-
tant clinical associations when HCV QS are analyzed by
HMA.
Discussion
In the current investigation, we found that the sensitivity
of Taq and HF-2 enzymes in amplifying the E2-HVR1
were similar to the qualitative Roche COBAS Amplicor
RT-PCR assay. The HF-2 enzyme generated more PCR
product and was more sensitive than Taq. For HALT-C
samples, QS diversity, expressed as an HMR, was similar
for both Taq and HF-2 enzymes, although Taq tended to
give higher diversity scores. HCV QS complexity was sig-
nificantly higher in samples amplified by Taq as com-
pared with samples amplified by HF-2. In contrast, in
HCV/HIV co-infected samples, diversity and complexity
scores were similar for both enzymes. The data from this
limited cohort suggest that QS results are not significantly
influenced by choice of polymerase when using the CFA
method.
Our data indicate that Taq induced errors provide inflated
estimates of HCV QS diversity and complexity. The data
are in accord with previous mathematical models of HCV
QS mutations [30], and a recent study that demonstrated
that Taq induced errors can generate minor QS variants
[31]. However, our results showed only a trend for
increased HMR for Taq amplified HALT-C samples as well
as for HMR and complexity scores for HCV/HIV co-
infected samples. Based on the current results, it would
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) scores generated with Taq or HF-2 p lymerases, in 20 HALT-C samples who were HCV RNA negative (N = 6) or HCV RNA positive (N = 14) a  week 20 (W 0) of pegyl ted IFN plus r bavirin th r pyFigure 4
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) scores generated with Taq 
or HF-2 polymerases, in 20 HALT-C samples who were HCV RNA negative (N = 6) or HCV RNA positive (N = 14) at week 
20 (W20) of pegylated IFN plus ribavirin therapy. The box plots represent the means and ranges of the HMR and complexity 
scores for 400 HVR1 clones amplified by each polymerase, for a total of 800 clones (20 patients × 20 clones/patient × 2 
enzymes). Error bars represent standard deviations. Wilcoxon Signed Ranks tests determined that the differences between 
enzymes and patient groups were not statistically significant.
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seem that Taq and proof-reading enzymes are acceptable
for HCV QS analyzed by CFA. However, further studies on
larger patient cohorts need to be performed.
Genetic evolution in the E2-HVR1 is believed to reflect
selective forces imposed on this domain by neutralizing
antibodies [4-10]. It is also possible that cell mediated
immune responses may impart selective pressures on
HVR1. In the face of immune pressure, the plasticity of the
HVR1 may allow the virus to persist. However, recent
studies suggest that the HVR1, although it is the most
variable region in the HCV genome, has certain con-
straints in its structure. It is intriguing that key basic resi-
dues are highly conserved, which maintains the
chemicophysical properties and conformation of the
HVR1 [33]. Because HVR1 is an exposed domain on the
E2 protein, these data suggest that the positively charged
HVR1 is involved in interactions with negatively charged
molecules such as lipids, proteins, or glycosaminoglycans
(GAGs). As such, the HVR1 may interact with GAGs facil-
itating host cell recognition and attachment [33]. In this
regard, it has recently been shown that high pretreatment
HCV QS diversity and complexity at baseline are associ-
ated with non-response to pegylated IFN ribavirin in
HALT-C patients [34].
HAART therapy appeared to increase HCV QS diversity
and complexity, regardless of the enzyme used, but this
did not reach statistical signficance in this small cohort.
These data are consistent with recent reports that suggest
that HAART-induced immune reconstitution drives HCV
QS evolution [18,19]. Additional prospective trials on
larger patient cohorts are required to further examine the
relationships between immune pressure, HCV QS evolu-
tion, and liver disease progression in patients co-infected
with HIV and HCV.
Materials and methods
Patients
Twenty patients who met entry criteria for the HALT-C
trial were included in the current study. Serum samples
from baseline (week 0; (W00)), prior to the start of IFN
therapy, were analyzed. Written, informed consent was
provided by all patients, following institutional and trial
specified IRB regulations. The design and conduct of the
HALT-C trial have been described [21]. Briefly, in the ini-
tial or lead-in course of therapy, all patients are treated
with pegylated interferon (Pegasys, Roche) plus ribavirin
for a period of 24 weeks, with virologic assessment at 20
weeks to assess whether or not they are virological
responders. Patients who are responders at week 20 con-
tinue treatment and receive a full course of 48 weeks of
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) values processed with Taq or HF-2 p lymerases, in 12 HCV/HIV co- nfected amples treated (N = 7) or not trea ed (N = 5  with HAARTFigure 5
Comparison of quasipecies genetic diversity (assessed by HMR, Panel A) and complexity (panel B) values processed with Taq 
or HF-2 polymerases, in 12 HCV/HIV co-infected samples treated (N = 7) or not treated (N = 5) with HAART. The box plots 
represent the means and ranges of the HMR and complexity scores for 240 HVR1 clones amplified by each polymerase, for a 
total of 480 clones (12 patients × 20 clones/patient × 2 enzymes). Error bars represent standard deviations. Wilcoxon Signed 
Ranks tests determined that all differences were not statistically significant.
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therapy. Those who remain HCV-positive in serum at 20
weeks are randomized to receive either continued low-
dose pegylated interferon (without further ribavirin) or
no further treatment beyond careful observation for the
ensuing 3.5 years. Immunology and virology ancillary
studies including QS analysis are aimed at increasing our
understanding of the complex interactions of virus and
host in this debilitating and widespread disease [34].
Samples from twelve patients co-infected with HCV and
HIV were also analyzed. Seven of these patients received
HAART, while 5 patients did not. All 32 patients were
infected with HCV of genotype 1.
E2-HVR1 RT-PCR Amplification and Cloning
HCV RNA was extracted from 100 µL of patient sera using
HCV RNA isolation columns (Qiagen). RNA was resus-
pended in DEPC-treated water, and converted into cDNA
using oligonucleotide primers and AMV reverse tran-
scriptase, as described previously [26]. The same cDNA
sample was then amplified using either Taq (Perkin
Elmer, Wellesley, MA) or Advantage High Fidelity 2 (HF-
2) (Clontech; Mountain View, CA) polymerases, using a
nested PCR reaction as described [26]. To provide a hot
start, AmpliWax (Perkin Elmer) beads were used to sepa-
rate Taq enzyme and primers, whereas the HF-2 enzyme
mixture contains an anti-Taq antibody. The primers gen-
erated the expected second round product of 176 base
pairs. PCR products were excised and purified with the
QiaEx purification system (Qiagen, Valencia, CA), ligated
into pCR2 vector, and transformed into TOP10 cells as
described [11].
Sensitivity of E2-HVR1 PCR Assay
To determine the sensitivity of the E2-HVR1 PCR assay
using Taq versus HF-2 polymerases, serial dilutions of an
HCV World Health Organization (WHO) international
standard [35] were prepared from 50,000 to 50 Interna-
tional Units/milliliter (IU/ml). RNA was extracted, con-
verted into cDNA and amplified by nested PCR as
described above. PCR products were separated on agarose
gels. Aliquots of WHO standards were also run through
the Roche Amplicor assay for internal comparison.
HCV RNA quantitation and genotyping
HCV RNA was qualitatively measured by RT-PCR using
the Roche COBAS Amplicor HCV test version 2.0
(RocheMolecular Systems, Branchburg, NJ), and quantita-
tively using Roche COBAS Amplicor HCV Monitor v. 2.0
(Roche Molecular Systems, Branchburg, NJ). Genotyping
was performed using the INNO-LiPA HCV II Kit (Bayer
Diagnostics, Emeryville, CA) All assays were performed
according to manufacturer's specifications.
Clonal Frequency Analysis (CFA)
For each cloned HVR1 PCR product, 20 colonies were
picked directly into tubes for re-amplification of the sec-
ond round PCR product. Thus, for each patient, 20 PCR
products representing 20 individual QS clones derived
from the baseline serum were analyzed. PCR products
were visualized on ethidium bromide-stained agarose
gels, and one HVR1 PCR product was randomly selected,
purified as described above, and end-labeled with 32P ATP
and T4 polynucleotide kinase. Unincorporated label was
separated with Centrisep columns (Princeton Separations,
Adelphia, NJ), and the labeled DNA probe was eluted
from the column. Labeled probe was hybridized directly
to each amplified PCR product for 2 hours at 55°C as
described [11]. Hybrids were separated on 6% non-dena-
turing polyacrylamide MDE gels (Cambrex, Baltimore,
MD) and visualized by autoradiography as described [11].
Data Analysis
QS complexity was determined by counting the total
number of unique gel shift patterns. QS genetic diversity
was determined by deriving the average heteroduplex
mobility of all clones relative to the homoduplex probe
control. A heteroduplex mobility ratio (HMR) was calcu-
lated by dividing the distance in millimeters (mm) from
the origin of the gel to the heteroduplex by the distance in
mm from the origin to the homoduplex control. In cases
where both strands of the heteroduplex were clearly dis-
tinguishable, the average of the distance of each strand of
the heteroduplex was used to calculate heteroduplex
mobility [25]. The HMRs for all variants in the population
were averaged to provide the final HMR value. Non-para-
metric Wilcoxon Signed Ranks tests were used to compare
the differences in QS complexity and diversity scores
between the different enzymes. Linear regression analysis
and Spearman's rank correlation tests were also used to
determine the correlation of Taq and Ad-HF2 measure-
ments of QS diversity and complexity.
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